{
  "RECAM_Score": 6,
  "Causality_Assessment": "Probable",
  "Domain_Scores": {
    "Domain_1_Temporal_Relationship": 2,
    "Domain_2_Risk_Factors": 0,
    "Domain_3_Clinical_Course": 1,
    "Domain_4_Concomitant_Drugs": 0,
    "Domain_5_Exclusion_of_Alternative_Causes": 3
  },
  "Non_DILI_Evidence": {
    "Viral_Hepatitis": "Excluded (negative serology for HAV, HBV, HCV)",
    "Alcohol": "Excluded (0 standard drinks per day)",
    "Biliary_Obstruction": "Excluded (imaging negative)",
    "Autoimmune_Hepatitis": "No evidence (negative ANA, ASMA, IgG)",
    "Ischemic_Hepatitis": "No evidence",
    "Sepsis": "No evidence",
    "Other_Viral_Infections": "No evidence (CMV, EBV, HSV negative or not tested)",
    "Malignant_Infiltration": "Excluded (<50% malignant infiltration)"
  },
  "Supporting_Evidence": {
    "Hepatocellular_Pattern": "R-value = 7.23 (ALT/ALP ratio > 5)",
    "Temporal_Relationship": "Onset 120 days after start, 3 days after stop",
    "Drug_Category": "Category E (known hepatotoxic drug)",
    "Demographics": "Female patient"
  },
  "Limitations": {
    "Missing_Data": "HCV RNA not tested, HEV IgM not tested, CMV/EBV/HSV IgM not tested",
    "Dechallenge_Response": "No data on liver enzyme decline after drug cessation",
    "Rechallenge": "No rechallenge data available"
  }
}